NASDAQHealth CareBiotechnologySnapshot 2026-07-31
Reading XOMA? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Daily closes. Earnings/event dots are placed inline.
The reason to own it still holds.
View ThesisRevenue growth is slowing — up about 13% over the past year and decelerating.
View GrowthMiddle-of-the-pack management execution.
View ManagementExpectations look high — the market is pricing in about 56% growth a year, above the roughly 6% analysts expect, leaving little room for error.
View ValuationThis stock is volatile — it swings about 1% on a typical day and fell roughly 42% in its worst 12-month stretch.
View RiskXOMA's growth depends on maintaining strong revenue guidance after recent changes. The company recently raised guidance, which supports its current valuation. It trades at 29× P/E, above the 18× peer median. The market expects more growth than XOMA has forecasted, indicating high expectations. A specific risk is if XOMA cuts guidance, which could harm credibility. Peer multiples imply a price about 10% below where it trades. This read is provisional.
Trailing returns as of 2026-07-14. XOMA is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 3 analysts currently covering XOMA (as of Jul 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A consensus fair price across 0 valuation methods, at three horizons. As of 2026-08-01. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Acquisition impacts revenue guidance and overall valuation.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-07-14. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
